Author

P. Milne

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell type annotation· 1 Assay:ChIP-seq· 1 Research Focus:chromatin & epigenetic regulation· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

M. Collin· 2 shared V. Bigley· 2 shared A. Burnett· 1 shared A. Dickinson· 1 shared A. Elder· 1 shared A. Grech· 1 shared A. Komkov· 1 shared A. Ptasinska· 1 shared

Activity by Year

2019-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

M. Collin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Epigenetic regulator genes direct lineage switching in MLL-AF4 leukaemia

R. Tirtakusuma, K. Szoltysek, P. Milne, V. V. Grinev, A. Ptasinska, C. Meyer, S. Nakjang, J. Y. Hehir-Kwa, D. Williamson, P. Cauchy, S. A. Assi, M. R. Imperato, F. Vogiatzi, S. Lin, M. Wunderlich, , M. J Thirman

This study shows that lineage switching in MLL-AF4 leukaemia is driven by dysregulation of epigenetic regulators like NuRD, leading to reprogramming of gene regulatory networks from B lymphoid to myeloid.

bioRxiv · Jul 16, 2021Cancer Biology

Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia

P. Milne, C. Wilhelm-Benartzi, M. R. Grunwald, V. Bigley, A. Publicover, S. Pagan, H. Marr, G. Jones, A. Dickinson, A. Grech, A. Burnett, N. Russell, M. Levis, S. Knapper, M. Collin

This paper shows that serum Flt3L levels correlate with progenitor cell mass and prognosis in AML, with lower levels linked to worse outcomes and relapse.

bioRxiv · Mar 25, 2019Cancer Biology